OCUGEN, INC. Form 8-K (June 1, 2020)

Summary

Current report on Form 8-K of Ocugen, Inc. with a date of earliest event reported of June 1, 2020, covering Item 8.01 (Other Events) and Item 9.01. The report states that on June 1, 2020 Ocugen issued a press release announcing the decision to discontinue the trial of OCU300 for ocular Graft vs. Host Disease. The press release is furnished as Exhibit 99.1 and incorporated by reference. The exhibit list names the press release dated June 1, 2020, and the report is signed June 1, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“OCUGEN, INC. Form 8-K (June 1, 2020).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ocgn-8-k-filed2020-06-01-0001628280-20-008718-27206d080f/, SHA-256 30eea7596d2480cc482b689aa77ba2c56ff7adbdc4491ace98f34e7389ba32c0.

Full text

8-K 1 ocgn-20200601x8k.htm 8-K html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

___________________________________________________________

FORM 8–K

___________________________________________________________

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 1, 2020

___________________________________________________________

OCUGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________________________

Delaware | 001-36751 | 04-3522315
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

5 Great Valley Parkway, Suite 160

Malvern, Pennsylvania 19355

(484) 328-4701

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

o Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))

o Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events

On June 1, 2020, Ocugen, Inc. issued a press release announcing the decision to discontinue the Phase 3 trial of OCU300 for ocular Graft vs. Host Disease. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

The following exhibit is being filed herewith:

(d) Exhibit

Exhibit No. | Document
99.1 | Press Release of Ocugen, Inc. dated June 1, 2020

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 1, 2020

OCUGEN, INC.
By: | /s/ Shankar Musunuri
Name: Shankar Musunuri
Title: Chief Executive Officer and Chairman

2

File and source

File: SEC_OCGN_8-K_filed2020-06-01_0001628280-20-008718.htm
Size: 32,543 bytes
SHA-256: 30eea7596d2480cc482b689aa77ba2c56ff7adbdc4491ace98f34e7389ba32c0
Our copy: SEC_OCGN_8-K_filed2020-06-01_0001628280-20-008718.htm
Original: www.sec.gov